




RealRate

PHARMACEUTICAL 2013

Statera Biopharma Inc
Rank 108 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Statera Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Statera Biopharma Inc is the variable Research and Development, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 240%, being 20% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	29,406
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,427
Liabilities, Non-Current	0
Other Assets	1,618
Other Compr. Net Income	4,642
Other Expenses	0
Other Liabilities	98
Other Net Income	11,203
Other Revenues	0
Property and Equipment	987
Research and Development	22,502
Selling, General and Administrative Expense	11,116

Output Variable	Value in 1000 USD
Assets	32,010
Liabilities	11,524
Expenses	33,617
Revenues	0
Stockholders Equity	20,486
Net Income	-22,415
Comprehensive Net Income	-20,093
BaseVar	46,498
ECR before Limited Liability	113%
Economic Capital Ratio	240%